NUREXONE BIOLOGIC INC (NRX.CA) Stock Price, Forecast & Analysis
Canada • TSX Venture Exchange • TSX-V:NRX • CA67059R1091
NRX.CA Key Statistics, Chart & Performance
The current stock price of NRX.CA is 0.7 CAD. In the past month the price increased by 7.69%. In the past year, price increased by 14.75%.
NRX.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NRX.CA. When comparing the yearly performance of all stocks, NRX.CA turns out to be only a medium performer in the overall market: it outperformed 47.02% of all stocks.
NRX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NRX.CA. NRX.CA may be in some trouble as it scores bad on both profitability and health.
NRX.CA Financial Highlights
Over the last trailing twelve months NRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -20.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -246.98% | ||
| ROE | -448.52% | ||
| Debt/Equity | 0.05 |
NRX.CA Forecast & Estimates
9 analysts have analysed NRX.CA and the average price target is 3.57 CAD. This implies a price increase of 410% is expected in the next year compared to the current price of 0.7.
NRX.CA Ownership
NRX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 555.63M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 381.69M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 144.36M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 75.07M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24 | 46.40M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 30.17M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 30.58M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.96M | ||
| MPH.CA | MEDICURE INC | N/A | 12.11M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 11.43M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.06M | ||
| KNE.CA | KANE BIOTECH INC | N/A | 6.69M |
Related stock screener links
About NRX.CA
Company Profile
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The firm focuses on research and development of pharmaceutical technologies.
Company Info
NUREXONE BIOLOGIC INC
Minus 1 Entry, Ground Floor Of Bldg B, Gutwirth Industrial Park, Technion City, Haifa
Haifa ALBERTA IL
Employees: 12
Phone: 972524803034
NUREXONE BIOLOGIC INC / NRX.CA FAQ
What does NRX do?
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The firm focuses on research and development of pharmaceutical technologies.
What is the stock price of NUREXONE BIOLOGIC INC today?
The current stock price of NRX.CA is 0.7 CAD. The price increased by 6.06% in the last trading session.
Does NRX stock pay dividends?
NRX.CA does not pay a dividend.
What is the ChartMill rating of NUREXONE BIOLOGIC INC stock?
NRX.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is NUREXONE BIOLOGIC INC (NRX.CA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NRX.CA.
Can you provide the market cap for NUREXONE BIOLOGIC INC?
NUREXONE BIOLOGIC INC (NRX.CA) has a market capitalization of 58.20M CAD. This makes NRX.CA a Micro Cap stock.